{"entity":{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","aka":[],"tldr":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease.","summary":"Neuroblastoma arises from developing sympathetic nerve cells, usually in the adrenal gland or along the spine, and is the most common cancer of infants and the most common extracranial solid tumour of childhood. It spans the widest clinical range in oncology: some infant tumours (stage MS) regress without treatment, while high-risk disease (about half of patients, defined by INRG stage, age over 18 months, MYCN amplification and other genomic features) is cured in only 50-60% despite the most intensive therapy given to children, which is where anti-GD2 antibodies and CAR-T have made their gains. ALK mutations (~10%) are the main druggable driver; MYCN, though not directly druggable, points to polyamine and ALK biology.\n\nHigh-risk therapy is a year-long sequence: five to six cycles of induction chemotherapy, surgery, myeloablative chemotherapy with autologous stem-cell rescue (tandem transplant in North America after ANBL0532; busulfan-melphalan single transplant in Europe after HR-NBL1), radiotherapy to the primary site, then anti-GD2 immunotherapy (dinutuximab or dinutuximab beta with GM-CSF; IL-2 abandoned after HR-NBL1) and isotretinoin. Anti-GD2 antibody raised survival by about 20 points (ANBL0032). Since December 2023, two years of oral eflornithine (DFMO) is approved as maintenance on the strength of an externally controlled study; naxitamab and irinotecan-temozolomide-dinutuximab treat relapse; lorlatinib is being added for ALK-aberrant tumours and 131I-MIBG tested in induction (ANBL1531).\n\nNeuroblastoma is also where CAR-T first produced lasting cures in a solid tumour: GD2-CART01 (Bambino Gesù, NEJM 2023) achieved 63% responses and 33% complete remissions in relapsed disease, with some remissions lasting more than a decade. The open questions are whether cell therapy can consolidate first-line remission, how to reduce the lifelong burden of hearing loss, infertility and second cancers in survivors, how to treat MYCN-amplified relapse, and how to bring anti-GD2 therapy to the majority of children in the world who cannot access it.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Neuroblastoma","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Neuroblastoma"}],"tags":["paediatric","spike"],"related":["paediatric-oncology-roadmap","wilms-tumor","hepatoblastoma","retinoblastoma","paediatric-germ-cell-tumours","anti-gd2-plus-chemo-relapse","il2-anti-gd2-caution"],"cancers":[],"sections":[],"technologies":["car-t","monoclonal-antibody","radioligand-therapy","proton-therapy","tandem-transplant","mibg-theranostics","autologous-stem-cell-transplant"],"targets":["alk","gd2"],"drugs":["isotretinoin"],"companies":["y-mabs","us-worldmeds","childrens-oncology-group"],"institutions":["mskcc","dana-farber","stanford","city-of-hope"],"pathways":[],"terms":["inrg-staging","mycn-amplification","efs","adcc","crs"],"trials":["ccss","nct04724369"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-pediatric-hematology-oncology","pediatric-hematology-and-oncology"],"dependsOn":[],"notes":[],"group":"paediatric","burden":"~7-8% of childhood cancers; ~800 US cases a year; median age at diagnosis ~18 months; 5-year survival >90% for low/intermediate risk and ~50-60% for high risk.","subtypes":["Very-low and low risk (L1, MS in infants; often observation or surgery alone)","Intermediate risk (L2, M in infants; moderate chemotherapy)","High risk (stage M >18 months, or MYCN-amplified at any age)","ALK-mutated or amplified (~10%; lorlatinib-responsive)","MYCN-amplified (~20%)","Relapsed/refractory (MIBG-avid vs non-avid; marrow vs soft-tissue)","Ganglioneuroblastoma / ganglioneuroma (differentiated spectrum)","Opsoclonus-myoclonus-associated (paraneoplastic)"],"biomarkers":["MYCN amplification","ALK mutation","Age, stage, ploidy","Segmental chromosome aberrations","INRG stage and image-defined risk factors","Age (<18 months)","MYCN amplification (FISH)","ALK mutation/amplification","11q aberration, 1p deletion, ploidy, segmental chromosomal aberrations","INPC histology","Urinary catecholamines (VMA/HVA)","123I-MIBG Curie score / 18F-MFBG PET","Bone marrow minimal residual disease (PHOX2B, TH qPCR)","GD2 expression (near-universal)"],"standardOfCare":[{"setting":"High-risk","approach":"Induction chemo → surgery → tandem transplant → RT → anti-GD2 + isotretinoin; lorlatinib if ALK-mutant.","refs":["lorlatinib","monoclonal-antibody"],"guideline":{"version":"NCI PDQ: Neuroblastoma Treatment (COG risk groups)","url":"https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq"}},{"setting":"Very-low / low risk (L1, MS)","approach":"Observation with serial imaging for asymptomatic L1/MS (many regress); surgery alone for resectable L1; short chemotherapy only for symptoms or progression.","refs":["inrg-staging","ultrasound"],"guideline":{"nccn":"COG/SIOPEN low-risk protocols (observation or surgery)","version":"COG ANBL1232 / SIOPEN LINES"}},{"setting":"Intermediate risk","approach":"2-8 cycles of moderate chemotherapy (carboplatin, etoposide, cyclophosphamide, doxorubicin) guided by response and biology; surgery; isotretinoin in some protocols.","refs":["doxorubicin","cytotoxic-chemotherapy","inrg-staging"]},{"setting":"High risk: induction","approach":"5-6 cycles (COG: topotecan-cyclophosphamide × 2 then cisplatin-etoposide, cyclophosphamide-doxorubicin-vincristine; SIOPEN: rapid COJEC); stem-cell harvest; ANBL1531 adds 131I-MIBG (randomised) or lorlatinib (ALK); ANBL17P1 adds dinutuximab to induction.","refs":["anbl1531","i131-mibg","lorlatinib","dinutuximab","doxorubicin","anbl17p1"],"guideline":{"nccn":"COG ANBL1531 backbone","version":"COG 2026"}},{"setting":"High risk: local control","approach":"Surgical resection of primary after induction (gross total where safe); external-beam radiotherapy 21.6 Gy to primary site (boost to residual) and MIBG-avid metastatic sites; proton therapy where available.","refs":["imrt-igrt","proton-therapy"]},{"setting":"High risk: consolidation","approach":"Tandem autologous transplant (thiotepa-cyclophosphamide, then CEM) in North America (ANBL0532); single busulfan-melphalan transplant in Europe (HR-NBL1).","refs":["tandem-transplant","autologous-stem-cell-transplant","anbl0532","hr-nbl1"],"guideline":{"nccn":"COG standard (tandem); SIOPEN standard (BuMel)","version":"2026"}},{"setting":"High risk: post-consolidation","approach":"Anti-GD2 antibody (dinutuximab + GM-CSF + isotretinoin; dinutuximab beta in Europe, no IL-2) × 5-6 cycles; then eflornithine maintenance 2 years (US, 2023).","refs":["dinutuximab","anbl0032","eflornithine","nmtrc003","il2-anti-gd2-caution"],"guideline":{"nccn":"Dinutuximab: FDA-approved standard; eflornithine: FDA-approved maintenance","version":"2026"}},{"setting":"Relapsed / refractory","approach":"Irinotecan-temozolomide + dinutuximab or naxitamab (ANBL1221); naxitamab + GM-CSF for marrow/bone disease; 131I-MIBG for MIBG-avid disease; lorlatinib for ALK; GD2 CAR-T (Italy, trials); DFMO-based maintenance; palliative radiotherapy.","refs":["dinutuximab","naxitamab","naxitamab-201","i131-mibg","lorlatinib","gd2-cart01","anti-gd2-plus-chemo-relapse","anbl1221"]},{"setting":"Survivorship","approach":"Audiology (platinum, DFMO), endocrine and fertility follow-up, cardiac surveillance (anthracycline), second-malignancy screening, neurocognitive support; lifelong late-effects clinic.","refs":["cardio-oncology"]}],"stateOfArt":["Anti-GD2 raised high-risk survival to ~60%.","GD2 CAR-T responses.","Anti-GD2 immunotherapy after transplant is standard worldwide (ANBL0032), with IL-2 removed after HR-NBL1 showed no benefit.","Tandem transplant (North America) and busulfan-melphalan (Europe) are the two evidence-based consolidation standards.","Eflornithine is the first oral maintenance therapy approved (December 2023), on an externally controlled study.","GD2 CAR-T produced durable complete remissions in relapsed neuroblastoma, the first such result in a childhood solid tumour.","ALK inhibition with lorlatinib for ALK-aberrant tumours and 131I-MIBG during induction are being tested in ANBL1531.","Risk-adapted de-escalation: many infants and low-risk patients are observed or cured with surgery alone."],"history":[{"year":1910,"title":"James Homer Wright describes neuroblastoma and its rosettes","refs":[]},{"year":1971,"title":"Spontaneous regression of stage IV-S (now MS) disease recognised (Evans staging)","refs":["inrg-staging"]},{"year":1983,"title":"MYCN amplification linked to aggressive disease (Brodeur, Schwab)","refs":["mycn-amplification"]},{"year":1985,"title":"131I-MIBG therapy first used in relapsed neuroblastoma","refs":["mibg-theranostics"]},{"year":1999,"title":"CCG-3891: myeloablative therapy with autologous rescue and isotretinoin improve survival","refs":["autologous-stem-cell-transplant"]},{"year":2008,"title":"ALK mutations identified as a hereditary and somatic driver","refs":["alk"]},{"year":2009,"title":"INRG classification unifies international risk grouping","refs":["inrg-staging"]},{"year":2010,"title":"Anti-GD2 (ch14.18) improves EFS","refs":[]},{"year":2010,"title":"ANBL0032: anti-GD2 immunotherapy raises survival ~20 points (NEJM)","refs":["anbl0032","dinutuximab"]},{"year":2015,"title":"Dinutuximab approved (US); dinutuximab beta in EU 2017","refs":["dinutuximab"]},{"year":2017,"title":"HR-NBL1: busulfan-melphalan beats CEM; IL-2 adds no benefit (2018)","refs":["hr-nbl1"]},{"year":2019,"title":"ANBL0532: tandem transplant improves EFS (JAMA)","refs":["anbl0532","tandem-transplant"]},{"year":2020,"title":"Naxitamab approved for relapsed disease (accelerated)","refs":["naxitamab","naxitamab-201"]},{"year":2023,"title":"GD2 CAR-T phase 1/2 in NEJM","refs":[]},{"year":2023,"title":"GD2-CART01 in NEJM: durable CAR-T remissions in a solid tumour; eflornithine approved (13 Dec)","refs":["gd2-cart01","eflornithine","nmtrc003"]},{"year":2025,"title":"Long-term GD2 CAR-T follow-up (Nature Medicine); naxitamab primary-refractory phase 2 (75% CR); eflornithine EU filing","refs":["gd2-cart01","naxitamab","eflornithine"]},{"year":2026,"title":"ANBL1531 MIBG randomisation maturing; ALK arm reports","refs":["anbl1531"]}],"pipeline":["armored-car","anbl1531","i131-mibg","lorlatinib","gd2-cart01","idea-gd2-car-t-frontline-consolidation","idea-mfbg-pet-replaces-mibg","mibg-theranostics","eflornithine","naxitamab","anti-gd2-plus-chemo-relapse","tandem-transplant","y-mabs"],"openProblems":["Relapsed high-risk disease.","Long-term toxicity of intensive therapy.","Relapsed high-risk neuroblastoma is rarely curable; MYCN-amplified relapse worst of all.","Anti-GD2 therapy causes severe neuropathic pain; less painful antibody formats (e.g., humanised, Fc-engineered) and CAR-T are needed.","Long-term toxicity of tandem transplant, cisplatin (hearing loss), and radiation in children who will live 70 years.","Eflornithine's approval rests on an external control; a randomised trial is unlikely, so uncertainty persists.","Access: anti-GD2 antibodies are expensive and unavailable in most low- and middle-income countries where most children with cancer live.","MYCN remains undruggable directly; polyamine and Aurora/BET strategies are indirect.","GD2 CAR-T needs randomised evidence and manufacturing at scale; only a few centres can deliver it.","Imaging burden: repeated MIBG scans with sedation; MFBG PET adoption is slow."],"parent":"childhood-cancers"},"route":"/cancers/neuroblastoma/","neighbours":{"roadmap":[{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/"}],"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/"},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/"},{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/"},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/"},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/"}],"pairing":[{"id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","route":"/pairings/anti-gd2-plus-chemo-relapse/"},{"id":"il2-anti-gd2-caution","kind":"pairing","name":"Caution: IL-2 added to anti-GD2 therapy","route":"/pairings/il2-anti-gd2-caution/"}],"technology":[{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/"},{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"rejuv-ayac-education-and-work","kind":"technology","name":"Education, work and the years that were interrupted","route":"/technologies/rejuv-ayac-education-and-work/"},{"id":"rejuv-paed-hearing","kind":"technology","name":"Hearing after platinum and cranial radiotherapy in a developing child","route":"/technologies/rejuv-paed-hearing/"},{"id":"hearing-after-platinum-chemotherapy","kind":"technology","name":"Hearing and tinnitus after platinum chemotherapy","route":"/technologies/hearing-after-platinum-chemotherapy/"},{"id":"rejuv-paed-chronic-disease-burden","kind":"technology","name":"How much illness childhood cancer survivors carry, and at what age","route":"/technologies/rejuv-paed-chronic-disease-burden/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"rejuv-paed-kidneys","kind":"technology","name":"Kidneys after cisplatin, ifosfamide, radiotherapy and nephrectomy in childhood","route":"/technologies/rejuv-paed-kidneys/"},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/"},{"id":"tandem-transplant","kind":"technology","name":"Tandem autologous transplant","route":"/technologies/tandem-transplant/"},{"id":"rejuv-paed-teeth-and-face","kind":"technology","name":"Teeth, jaws and facial growth after treatment in childhood","route":"/technologies/rejuv-paed-teeth-and-face/"},{"id":"rejuv-paed-cog-ltfu-guidelines","kind":"technology","name":"The Children's Oncology Group Long-Term Follow-Up Guidelines","route":"/technologies/rejuv-paed-cog-ltfu-guidelines/"},{"id":"rejuv-paed-transition-to-adult-care","kind":"technology","name":"The handover from children's to adult services, where follow-up falls away","route":"/technologies/rejuv-paed-transition-to-adult-care/"},{"id":"rejuv-paed-heart","kind":"technology","name":"The heart after anthracyclines and chest radiotherapy in childhood","route":"/technologies/rejuv-paed-heart/"},{"id":"ultrasound","kind":"technology","name":"Ultrasound","route":"/technologies/ultrasound/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"bcorl1","kind":"target","name":"BCORL1","route":"/targets/bcorl1/"},{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/"},{"id":"dot1l","kind":"target","name":"DOT1L","route":"/targets/dot1l/"},{"id":"etv4","kind":"target","name":"ETV4","route":"/targets/etv4/"},{"id":"fbln2","kind":"target","name":"FBLN2","route":"/targets/fbln2/"},{"id":"fbn2","kind":"target","name":"FBN2","route":"/targets/fbn2/"},{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/"},{"id":"msi2","kind":"target","name":"MSI2","route":"/targets/msi2/"},{"id":"mycn","kind":"target","name":"MYCN (N-myc)","route":"/targets/mycn/"},{"id":"myo5a","kind":"target","name":"MYO5A","route":"/targets/myo5a/"},{"id":"pcna","kind":"target","name":"PCNA","route":"/targets/pcna/"},{"id":"phox2b","kind":"target","name":"PHOX2B","route":"/targets/phox2b/"},{"id":"prdm2","kind":"target","name":"PRDM2","route":"/targets/prdm2/"},{"id":"prune2","kind":"target","name":"PRUNE2","route":"/targets/prune2/"},{"id":"tnc","kind":"target","name":"TNC","route":"/targets/tnc/"}],"drug":[{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"isotretinoin","kind":"drug","name":"Isotretinoin","route":"/drugs/isotretinoin/"},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"},{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/"},{"id":"sodium-thiosulfate","kind":"drug","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/"},{"id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/"},{"id":"cclg","kind":"company","name":"Children's Cancer and Leukaemia Group","route":"/companies/cclg/"},{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"},{"id":"itcc","kind":"company","name":"Innovative Therapies for Children with Cancer (ITCC)","route":"/companies/itcc/"},{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","route":"/companies/partner-therapeutics/"},{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","route":"/companies/united-therapeutics/"},{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/"},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/"}],"institution":[{"id":"accelerate-platform","kind":"institution","name":"ACCELERATE","route":"/institutions/accelerate-platform/"},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/"},{"id":"cche-57357","kind":"institution","name":"Children's Cancer Hospital Egypt 57357","route":"/institutions/cche-57357/"},{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/"},{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/"},{"id":"baylor-duncan","kind":"institution","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","route":"/institutions/baylor-duncan/"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/"},{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","route":"/institutions/great-ormond-street/"},{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/"},{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","route":"/institutions/istanbul-oncology-institute/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/"},{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/"},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/"},{"id":"siop-europe","kind":"institution","name":"SIOP Europe (European Society for Paediatric Oncology)","route":"/institutions/siop-europe/"},{"id":"st-anna-ccri-vienna","kind":"institution","name":"St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI)","route":"/institutions/st-anna-ccri-vienna/"},{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/"},{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/"},{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/"},{"id":"texas-childrens","kind":"institution","name":"Texas Children's Cancer and Hematology Center","route":"/institutions/texas-childrens/"},{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/"},{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/"},{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/"},{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/"}],"term":[{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/"},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/"},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"},{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/"},{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","route":"/terms/inrg-staging/"},{"id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/"},{"id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/"},{"id":"race-for-children-act","kind":"term","name":"RACE for Children Act","route":"/terms/race-for-children-act/"},{"id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/"},{"id":"urinary-catecholamines","kind":"term","name":"Urinary catecholamine metabolites (VMA and HVA)","route":"/terms/urinary-catecholamines/"}],"trial":[{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/"},{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/"},{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/"},{"id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","route":"/trials/nct05701306/"},{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/"},{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/"},{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/"},{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/"},{"id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","route":"/trials/nct07502287/"},{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/"},{"id":"nct00004157","kind":"trial","name":"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","route":"/trials/nct00004157/"},{"id":"naxitamab-201","kind":"trial","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/"},{"id":"nmtrc003","kind":"trial","name":"NMTRC003/003B (DFMO maintenance)","route":"/trials/nmtrc003/"},{"id":"nct04724369","kind":"trial","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","route":"/trials/nct04724369/"},{"id":"hr-nbl1","kind":"trial","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/"},{"id":"nct00716976","kind":"trial","name":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","route":"/trials/nct00716976/"}],"journal":[{"id":"journal-of-pediatric-hematology-oncology","kind":"journal","name":"Journal of pediatric hematology/oncology","route":"/journals/journal-of-pediatric-hematology-oncology/"},{"id":"pediatric-hematology-and-oncology","kind":"journal","name":"Pediatric hematology and oncology","route":"/journals/pediatric-hematology-and-oncology/"}],"idea":[{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/"},{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/"},{"id":"idea-acc-paediatric-palliative-in-every-childhood-unit","kind":"idea","name":"A paediatric palliative care team in every childhood cancer unit","route":"/ideas/idea-acc-paediatric-palliative-in-every-childhood-unit/"},{"id":"idea-fund-amc-paediatric-rare","kind":"idea","name":"Advance market commitments for paediatric and rare cancer drugs","route":"/ideas/idea-fund-amc-paediatric-rare/"},{"id":"idea-data-paediatric-rwe-consortium","kind":"idea","name":"An international consortium pooling the outcome of every treated child with cancer","route":"/ideas/idea-data-paediatric-rwe-consortium/"},{"id":"idea-bio1-rare-cancer-organoid-bank","kind":"idea","name":"An open organoid bank for cancers too rare to have models","route":"/ideas/idea-bio1-rare-cancer-organoid-bank/"},{"id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/"},{"id":"idea-bio2-paediatric-first-development","kind":"idea","name":"Develop drugs in children first when the target is a children's target","route":"/ideas/idea-bio2-paediatric-first-development/"},{"id":"idea-fund-paediatric-deferral-escrow","kind":"idea","name":"Escrow a share of adult revenue until the paediatric study is done","route":"/ideas/idea-fund-paediatric-deferral-escrow/"},{"id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/"},{"id":"idea-acc-childhood-medicines-platform-scale","kind":"idea","name":"Guaranteed-quality childhood cancer medicines free of charge in 50 countries","route":"/ideas/idea-acc-childhood-medicines-platform-scale/"},{"id":"idea-tr2-paediatric-combo-prea","kind":"idea","name":"Make paediatric combination studies part of every relevant adult cancer drug approval","route":"/ideas/idea-tr2-paediatric-combo-prea/"},{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/"},{"id":"idea-reg-single-paediatric-plan","kind":"idea","name":"One global paediatric cancer development plan instead of separate FDA and EMA plans","route":"/ideas/idea-reg-single-paediatric-plan/"},{"id":"idea-moon-open-source-oncology-drug-discovery","kind":"idea","name":"Open-source drug discovery to clinical proof of concept for neglected cancers","route":"/ideas/idea-moon-open-source-oncology-drug-discovery/"},{"id":"idea-bio2-rare-cancer-prize-fund","kind":"idea","name":"Pay a prize for rare cancer drugs instead of hoping for a market","route":"/ideas/idea-bio2-rare-cancer-prize-fund/"},{"id":"idea-bio1-epigenetic-silencing-in-vivo","kind":"idea","name":"Switch off an undruggable oncogene permanently with epigenetic editing","route":"/ideas/idea-bio1-epigenetic-silencing-in-vivo/"}],"person":[{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/"},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/"},{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","route":"/people/angelika-eggert/"},{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/"},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/"},{"id":"john-maris","kind":"person","name":"John M. Maris","route":"/people/john-maris/"},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/"},{"id":"louis-chesler","kind":"person","name":"Louis Chesler","route":"/people/louis-chesler/"},{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","route":"/people/meredith-irwin/"},{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","route":"/people/nai-kong-cheung/"},{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","route":"/people/nikolaus-rajewsky/"},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/"},{"id":"ruth-ladenstein","kind":"person","name":"Ruth Ladenstein","route":"/people/ruth-ladenstein/"},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/"},{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/"},{"id":"yael-mosse","kind":"person","name":"Yael P. Mossé","route":"/people/yael-mosse/"}],"bottleneck":[{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}],"pathway":[{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/"}],"collection":[{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/"},{"id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/"}],"biomarker":[{"id":"mycn-amp","kind":"biomarker","name":"MYCN amplification","route":"/biomarkers/mycn-amp/"}],"paper":[{"id":"paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020","kind":"paper","name":"ANBL1221 expansion: irinotecan, temozolomide and dinutuximab with GM-CSF in refractory or relapsed neuroblastoma","route":"/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/"},{"id":"paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017","kind":"paper","name":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma","route":"/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/"}]}}